NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Acquires $12,775.86 in Stock

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) major shareholder Poplar Point Capital Partners acquired 21,654 shares of the business’s stock in a transaction on Monday, March 31st. The shares were purchased at an average cost of $0.59 per share, for a total transaction of $12,775.86. Following the completion of the transaction, the insider now owns 971,654 shares in the company, valued at approximately $573,275.86. This represents a 2.28 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

• On Friday, January 31st, Poplar Point Capital Partners bought 70,685 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.65 per share, with a total value of $45,945.25.
• On Monday, January 27th, Poplar Point Capital Partners acquired 31,703 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.69 per share, with a total value of $21,875.07.
• On Thursday, February 20th, Poplar Point Capital Partners bought 1,836 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.63 per share, for a total transaction of $1,156.68.
• On Tuesday, February 18th, Poplar Point Capital Partners purchased 3,222 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.66 per share, with a total value of $2,126.52.
• On Monday, February 3rd, Poplar Point Capital Partners acquired 2,597 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $1,662.08.
• On Friday, March 7th, Poplar Point Capital Partners bought 102 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.55 per share, with a total value of $56.10.
• On Tuesday, March 4th, Poplar Point Capital Partners purchased 4,000 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.58 per share, for a total transaction of $2,320.00.
• On Thursday, February 27th, Poplar Point Capital Partners acquired 385 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.61 per share, with a total value of $234.85.
• On Tuesday, February 25th, Poplar Point Capital Partners bought 25,033 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.62 per share, for a total transaction of $15,520.46.
• On Friday, March 14th, Poplar Point Capital Partners purchased 25,511 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.63 per share, with a total value of $16,071.93.

NovaBay Pharmaceuticals Trading Up 2.0 %

NBY stock opened at $0.60 on Friday. The stock’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $0.63. NovaBay Pharmaceuticals, Inc. has a 12-month low of $0.36 and a 12-month high of $9.08. The stock has a market capitalization of $3.49 million, a PE ratio of -0.01 and a beta of 0.90.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals in a research note on Friday. They set a “hold” rating for the company.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.